Name: R406
Brand: Selleck Chemicals
SKU: S2194
Rating: 5 (82 reviews)

CAS No. 841290-81-1

Selleck's R406 has been cited by 82 publications

Purity & Quality Control

Choose Selective Syk Inhibitors

Related Compound Libraries

Other Syk Products

Download Inhibitor Catalog

Syk Signaling Pathway Map

Biological Activity

Description

R406 is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 induces apoptosis. Phase 1.

Features

Lead drug candidate for rheumatoid arthritis.

Targets

Flt3 ^[1] (Cell-free assay)	Syk ^[1] (Cell-free assay)
	41 nM

In vitro

R406 is a potent inhibitor of immunoglobulin E (IgE)- and IgG-mediated activation of Fc receptor signaling. R406 inhibits the anti-IgE-induced production and release of LTC4 and cytokines and chemokines, including TNFα, IL-8, and GM-CSF. R406 inhibits phosphorylation of Syk substrate linker for activation of T cells in mast cells and B-cell linker protein/SLP65 in B cells. R406 binds to the ATP binding pocket of Syk and inhibits its kinase activity as an ATP-competitive inhibitor with K_i of 30 nM. R406 blocks Syk-dependent FcR-mediated activation of monocytes/macrophages and neutrophils and Bcr-mediated activation of B lymphocytes. ^[1] R406 significantly induces chronic lymphocytic leukemia (CLL) cell apoptosis in nurselike cells cocultures and blocks CCL3 and CCL4 secretion by CLL cells in response to B-cell antigen receptor (Bcr) triggering. ^[2] R406 is a potent inhibitor of platelet signaling and functions initiated by FcγRIIA cross-linking by specific antibodies or by sera from HIT patients. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

AMO-1	NHv2VHpHfW6ldHnvckBCe3OjeR?=	M1\PclEh\|ryP	NYizOW5YO8LiaB?=		MnjIdoVlfWOnczDtbYdz[XSrb39CpC=>	NGjFelc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1NVc3OSd-Mk[yOVE4PjF:L3G+
U266	MoD6SpVv[3Srb36gRZN{[Xl?	MmHqNUDPxE1?	NXz4cJZCO8LiaB?=		M3zGO5Jm\HWlZYOgcYloemG2aX;uxsA>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3MUe2NUc,OjZ{NUG3OlE9N2F-
Jeko-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIrQbHI1QCCq		M{Pqd2lEPTB;NT6wOlgzPiEQvF2=	NX;FSZpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U4PTVpPkK1PFM2PzV3PD;hQi=>
Mino	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWPjUGN3PDhiaB?=		MVHJR\|UxRTVwN{C4OVQh\|ryP	MmDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{W3OVUoRjJ3OEO1O\|U2RC:jPh?=
Jeko-1	M1;xeGFxd3C2b4Ppd{BCe3OjeR?=	M4fFdVXDqM7:TR?=	M1\QWlI1KGh?		NVvNepZKcW6mdXPld{AzPS5zwrFCteKhOy5{wrClJIFxd3C2b4Ppdy=>	M2XxV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1O\|U2Lz5{NUizOVc2PTxxYU6=
primary MCL	MV;BdI9xfG:\|aYOgRZN{[Xl?	MoO0NkDDvU1?	NXzWR5IzOjRiaB?=		NX7Me5B1cW6lcnXhd4V{KHOrZ37p[olk[W62bImgZZBweHSxc3nzxsA>	M4riVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4N\|c{Lz5{NUO4PFM4OzxxYU6=
PBMCs	MoTIR4VtdCCYaXHibYxqfHliQYPzZZk>	NYLJdGJLOC13MDFOwG0>	NHvSNGIzPCCq	Mn7lSG1UVw>?	NWXiUoVGcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	M1K2XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK3PFYzLz5{NUGyO\|g3OjxxYU6=
PBMCs	Ml;BSpVv[3Srb36gRZN{[Xl?	NFz6ZYI2KM7:TR?=	NXW1b3VLOSCq	NYTqO3lDTE2VTx?=	MVnk[YNz\WG\|ZYOgeIhmKGOnbHygcYloemG2aX;u	NHXtc3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyO\|g3Oid-MkWxNlc5PjJ:L3G+
CFSE-CD4+ T	M4PneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnhZlAxNjB4MkWtNUDPxE1?	M1rHUVQh\A>?		M2jPWIJtd2OtczDwdo9tcW[ncnH0bY9vKG:oIFfWTGQu\GW{aY\l[EBETDRtwrDUJINmdGy\|IHHu[EBETDFzYjxCpINmdGy\|	NVnT[IR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|k6QDJpPkK0Olc6QTh{PD;hQi=>
CFSE-CD11b+	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXjSoUxNjB4MkWtNUDPxE1?	Mn\PPEBl		NGnBfXljdG:la4OgdJJwdGmoZYLheIlwdiCxZjDHWmhFNWSncnn2[YQhS0R2K9MgWEBk\WyuczDhcoQhS0RzMXKrxsBk\Wyucx?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5OUm4Nkc,OjR4N{m5PFI9N2F-
HMECs	NH25e4RHfW6ldHnvckBCe3OjeR?=	MUOwMVExKM7:TR?=	NYPzcm1iOjBibXnu		MX7pcohq[mm2czDWSWdHNXO2aX31cIF1\WRicnXs[YF{\SCxZjDOUy=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{OUW0OEc,OjR\|Mkm1OFQ9N2F-
AB5	MXPBdI9xfG:\|aYOgRZN{[Xl?	MoDoNE0zNjVizszN	MnjYOFghcA>?	NXLGTYlPTE2VTx?=	NEHyfnJqdmS3Y3XzJIFxd3C2b4Ppdy=>	M4P2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m4PVEyLz5{M{O5PFkyOTxxYU6=
JB7	NYiwWWhZSXCxcITvd4l{KEG\|c3H5	NVvjdHJnOC1{LkWg{txO	MljNOFghcA>?	M3LtVGROW09?	M1q0S4lv\HWlZYOgZZBweHSxc3nz	NFvzT\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O5PFkyOSd-MkOzPVg6OTF:L3G+
AB5	NXL6NYpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXLNo5IOC1{LkWg{txO	MYS0PEBp	NWfVXnV5TE2VTx?=	NYnCfYdTcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=>	M2XCZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m4PVEyLz5{M{O5PFkyOTxxYU6=
JB7	M2HxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUWwMVIvPSEQvF2=	MlPiOFghcA>?	NH75OnFFVVOR	M2fPbYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	NWfhVW9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVg6OTFpPkKzN\|k5QTFzPD;hQi=>
RL	NYHBN3lKTnWwY4Tpc44hSXO\|YYm=	MlTVNk42NzVizszN	M3;pdFI1NzR6IHi=	NGPtNZNFVVOR	M1TwSolv\HWlZYOgZUBxd3SnboSg[IVkemWjc3WgbY4hVU2SLUmgcXJPSSCneIDy[ZN{cW:w	NFm3XIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlk3PSd-MkG5NlY6PjV:L3G+
RL	M1GzbmZ2dmO2aX;uJGF{e2G7	NGXHSoYyNzJwNTFOwG0>	MXKyOEBp	MoLISG1UVw>?	Mm\FdoVlfWOnczD0bIUh[WO2aY\heIlwdiCxZjDBb5Qh[W6mIIC3NHM3Uw>?	NWK0bY9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlY6PjVpPkKxPVI3QTZ3PD;hQi=>
platelet	MYLGeY5kfGmxbjDBd5NigQ>?	NF\Yc2IyyqEQvH2=	M1WzUFUhdWmw		NELsVoFqdmirYnn0d{BH[87\|UlnJRU1u\WSrYYTl[EBxdGG2ZXzleEBi\2e{ZXfheIlwdg>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh2OE[5OEc,OjF6NEi2PVQ9N2F-
platelet	NV\QbJk6TnWwY4Tpc44hSXO\|YYm=	MVKwMlA2NzFxMj61JO69VQ>?	Mn7sOUBucW5?		M2n4Z4lvcGmkaYTzJJRp\SC\|aXfuZYxqdmdibXXjbIFvcXOvczDkc5dve3S{ZXHtJI9nKE[lzsPSTWlC	M{O1UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOES4Olk1Lz5{MUi0PFY6PDxxYU6=
DoHH2	MW\BdI9xfG:\|aYOgRZN{[Xl?	NFzoPGkxNzNxMUCg{txO	NHvUUHk1QCCq		NGDzOYFqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueR?=	MkHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{W0NFgoRjJyOEe1OFA5RC:jPh?=
Jeko-1	NF;NUnNCeG:ydH;zbZMhSXO\|YYm=	NULDd2hkOC9\|L{GwJO69VQ>?	NV7rZ4Z1PDhiaB?=		NVfWfo5ZcW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bIm=	MmGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6N{W0NFgoRjJyOEe1OFA5RC:jPh?=
Raji	MkLTRZBweHSxc3nzJGF{e2G7	NV\2cYRPOC9\|L{GwJO69VQ>?	MWG0PEBp		NHTiT5NqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueR?=	NWn3eFQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|U1ODhpPkKwPFc2PDB6PD;hQi=>
DHL4	MVfBdI9xfG:\|aYOgRZN{[Xl?	MYWwM\|EwPCEQvF2=	NWftOGJbQTZiaB?=		NV:2bWwzcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NUHNXFM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY7	NW\6cVl{SXCxcITvd4l{KEG\|c3H5	M2nxPVAwOS92IN88US=>	MmjRPVYhcA>?		MYXpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NV;ZNY1tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY3	NIHQZWVCeG:ydH;zbZMhSXO\|YYm=	MnT2NE8yNzRizszN	NV7GVpROQTZiaB?=		MXHpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NYfKU29jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
DHL6	NET0SmdCeG:ydH;zbZMhSXO\|YYm=	MUOwM\|EwPCEQvF2=	MU[5OkBp		M1rqbIlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY10	MknyRZBweHSxc3nzJGF{e2G7	M2DNclAwOS92IN88US=>	NWrEUmRGQTZiaB?=		MoPpbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	M{TtTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL10	MmD6RZBweHSxc3nzJGF{e2G7	M2XZVVAwOS92IN88US=>	M2TT[Fk3KGh?		MVnpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NEnURYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
Wsu-NHL	M13xfWFxd3C2b4Ppd{BCe3OjeR?=	NYGwcG1lOC9zL{Sg{txO	MlrNPVYhcA>?		NETPVoRqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY18	NGjoZ4RCeG:ydH;zbZMhSXO\|YYm=	NUfWZmo6OC9zL{Sg{txO	MoCxPVYhcA>?		NEPwSZZqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	M2jOe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY1	NFHXOldCeG:ydH;zbZMhSXO\|YYm=	NIjBUlYxNzFxNDFOwG0>	MWm5OkBp		M2ftUYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm=	M{XYZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL8	NGDzeINCeG:ydH;zbZMhSXO\|YYm=	NGPYVowxNzFxNDFOwG0>	M{CzXVk3KGh?		NIPF[2NqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	Ml3lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
DHL4	NWHEXWJwSXCxcITvd4l{KEG\|c3H5	NVvSTY5vPCEQvF2=	M3vTZlk3KGh?		MX7pcoR2[2W\|IHPs[YF3[WenIH;mJINie3Cjc3XzJFkh[W6mIEOsJIJ2fCCwb4SgZ4F{eGG\|ZTC4	M1\vWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL6	M3[3[WFxd3C2b4Ppd{BCe3OjeR?=	NYq5fmU{PCEQvF2=	NIj2WFE6PiCq		M4m3eIlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhQSCjbnSgN{wh[nW2IH7veEBk[XOyYYPlJFg>	M3;QNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY3	M1i2NGFxd3C2b4Ppd{BCe3OjeR?=	Ml7WOEDPxE1?	MVq5OkBp		MWDpcoR2[2W\|IHPs[YF3[WenIH;mJINie3Cjc3XzJFkh[W6mIEOsJIJ2fCCwb4SgZ4F{eGG\|ZTC4	NX:x[XhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY7	NUjMPWZuSXCxcITvd4l{KEG\|c3H5	M4Cw[VQh\|ryP	NHjxOpo6PiCq		M1fWT4lv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhQSCjbnSgN{wh[nW2IH7veEBk[XOyYYPlJFg>	M2\YN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL4	NFXwSFhHfW6ldHnvckBCe3OjeR?=	M1LUbVQh\|ryP	NVXCdFN3OTZiaB?=		NHjqeFlqdmirYnn0d{B1d26rYzDCUG5MKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvci=>	NV;EbXRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY7	NVX6O5R1TnWwY4Tpc44hSXO\|YYm=	MVq0JO69VQ>?	NHLHfWkyPiCq		MoXRbY5pcWKrdIOgeI9vcWNiQlzOT{B1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb36=	NYG1NppMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY3	MUTGeY5kfGmxbjDBd5NigQ>?	NIjhbZE1KM7:TR?=	M3f0UVE3KGh?		MUnpcohq[mm2czD0c45q[yCETF7LJJR6em:\|aX7lJJBpd3OyaH;yfYxifGmxbh?=	NWP1[YxRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
DHL6	M3vkcWZ2dmO2aX;uJGF{e2G7	MUK0JO69VQ>?	NYHWbHdOOTZiaB?=		M3TjPIlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u	M3LRZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY10	MmjCSpVv[3Srb36gRZN{[Xl?	NXK4W3pVPCEQvF2=	MlTaNVYhcA>?		NV7sTmVScW6qaXLpeJMhfG:waXOgRmxPUyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44>	M{\r[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
Wsu-NHL	NVzadJpkTnWwY4Tpc44hSXO\|YYm=	NVr2fXJpPCEQvF2=	MkDTNVYhcA>?		MYjpcohq[mm2czD0c45q[yCETF7LJJR6em:\|aX7lJJBpd3OyaH;yfYxifGmxbh?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY18	MmfNSpVv[3Srb36gRZN{[Xl?	MmfPOEDPxE1?	MV:xOkBp		NWDobGtpcW6qaXLpeJMhfG:waXOgRmxPUyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44>	MnrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
MV411	MYTGeY5kfGmxbjDhd5NigQ>?		Mmf1O\|IhcHK\|		M1XPO2lvcGmkaYTpc44hd2ZiRnz0N{BqdiCqdX3hckBOXjRzMTDj[YxteyCjc4Pld5Nm\CCjczDhd5Nme3OnZDDhd{Bxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BqdmO3YnH0bY9vKGK7IIPw[YN1em:yaH;0c41mfHK7LDDFR\|UxRTBwMEJOwG0v	M1Xm[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{e5OVE1Lz5{NEe3PVUyPDxxYU6=
TF1	NGPFVXRHfW6ldHnvckBie3OjeR?=		M1LzVlEhcHJ?		NX7hZmI1UW6qaXLpeIlwdiCxZjDKZYszKGmwIHXyfZRpem:yb3nleIlvNXO2aX31cIF1\WRiaIXtZY4hXEZzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHzd4V{e2WmIHHzJJBpd3OyaH:tV5RifDViYX\0[ZIhOSCqcjDpcoN2[mG2aX;uMEBGSzVyPUCuNFE{\|ryPLh?=	M33WcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{e5OVE1Lz5{NEe3PVUyPDxxYU6=
neutrophils	NV;4RlJQTnWwY4Tpc44h[XO\|YYm=				NVjleYREUW6qaXLpeIlwdiCxZjDTXWshcW5iaIXtZY4hdmW3dILvdIhqdHNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGZk\XC\|aXzvcnIyN0[lZ3HtcYFTNW2nZHnheIVlKHOrZ37hcIlv\yC{ZYPwc45{\XNuIFXDOVA:OC5yM{ROwG0v	M2TTOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkW3NlE{Lz5{MkK1O\|IyOzxxYU6=
SK-M-MC	NEjXRnpHfW6ldHnvckBie3OjeR?=		NFL2OXIyKGi{		M1TPe2lvcGmkaYTpc44hd2ZiUnX0JIlvKGi3bXHuJHNMNU1vTVOgZ4VtdHNiYYPz[ZN{\WRiYYOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2aX;uJIFnfGW{IEGgbJIhcW6ldXLheIlwdixiRVO1NF0xNjB\|Nt88UU4>	MoLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
mast cells	MX3GeY5kfGmxbjDhd5NigQ>?		NEL1WnYyKGi{		NVXtdogyUW6qaXLpeIlwdiCxZjDjT4l1KGmwIIP0[Y0h[2WubDDmZYN1d3Jvc4TpcZVt[XSnZDDic45mKG2jcoLve{Bl\XKrdnXkJI1wfXOnIH3hd5Qh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2aX;uJIFnfGW{IEGgbJIhcW6ldXLheIlwdixiRVO1NF0xNjB2Nt88UU4>	NVjCPG9uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
B-cells	NFrDN5dHfW6ldHnvckBie3OjeR?=				M2jPSWlvcGmkaYTpc44hd2ZiU2nLJIlvKGi3bXHuJGIu[2WubIOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKE[lZYDzbYxwdlJzL1\j[4FudWGULX3l[IlifGWmIIPp[45idGmwZzDy[ZNxd26\|ZYOsJGVEPTB;MD6wOFjPxE1w	Mo\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{NUeyNVMoRjJ{MkW3NlE{RC:jPh?=
Ramos	NIrhXYpHfW6ldHnvckBie3OjeR?=				MULJcohq[mm2aX;uJI9nKFO7azDpckBidnSraIXtZY4hUWePLYP0bY12dGG2ZXSgbJVu[W5iUnHtc5Mh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iQlPSMY1m\GmjdHXkJGJNVkticHjvd5Bpd3K7bHH0bY9vKGK7IHPlcIx2dGG{IHHzd4F6NCCHQ{WwQVAvODV\|zszNMi=>	MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
mesangial cells	NFjYNZRHfW6ldHnvckBie3OjeR?=				NGLldJNKdmirYnn0bY9vKG:oIGPZT{BqdiCldXz0eZJm\CCqdX3hckBu\XOjbnfpZYwh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIF\j[ZB{cWyxbmKxM2Zk\2GvbXHSMY1m\GmjdHXkJJNq\26jbHnu[{Bz\XOyb37z[ZMtKEWFNUC9NE4xPTcQvF2u	NYDxWmRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF\|PD;hQi=>
SK-N-SH	NV\X[Vg{TnWwY4Tpc44h[XO\|YYm=				NXX1R5lWUW6qaXLpeIlwdiCxZjDS[ZQhcW5iaIXtZY4hW0tvTj3TTEBk\WyuczygSWM2OD1yLkC4{txONg>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ3N{KxN{c,OjJ{NUeyNVM9N2F-
mouse bone marrow cells	NUX2N3JbTnWwY4Tpc44h[XO\|YYm=				MnrDTY5pcWKrdHnvckBw\iCLTEOg[IVx\W6mZX70JJBzd2yrZnXyZZRqd25iaX6gR\|U4N0JzNjDtc5V{\SCkb37lJI1ienKxdzDj[YxteyC3c3nu[{BcO0ifdHj5cYllcW6nIHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwQVAvOTR5zszNMi=>	MmH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mk[4NFYoRjJ2N{K2PFA3RC:jPh?=
B-cells	M3z3OGZ2dmO2aX;uJIF{e2G7		Mo\CNUBpeg>?		MnTrTY5pcWKrdHnvckBw\iCVeXugbY4h[WyyaHHJ[20ue3SrbYXsZZRm\CCqdX3hckBDKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkAyKGi{IHnuZ5Vj[XSrb36gZpkh\myxdzDjfZRwdWW2comsJGVEPTB;MD6xOVHPxE1w	MlfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
THP1	MlvLSpVv[3Srb36gZZN{[Xl?				M1r1fGlvcGmkaYTpc44hd2ZiU2nLJIlvKGi3bXHuJHRJWDFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGZk\XC\|aXzvcnIyN0[lZ3HtcYFTNW2nZHnheIVlKHOrZ37hcIlv\yC{ZYPwc45{\XNuIFXDOVA:OC5zN{JOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ3N{KxN{c,OjJ{NUeyNVM9N2F-
B-cells	NYPCPGhXTnWwY4Tpc44h[XO\|YYm=		MV[xJIhz		NX;peG5yUW6qaXLpeIlwdiCxZjDTfYshcW5iYXzwbIFK\01vc4TpcZVt[XSnZDDoeY1idiCEIHPlcIx{KGG\|c3Xzd4VlKGG\|IFPEPFYh\XiycnXzd4lwdiCjZoTldkAyKGi{IHnuZ5Vj[XSrb36gZpkh\myxdzDjfZRwdWW2comsJGVEPTB;MD6zN\|XPxE1w	MkPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
Ramos	Mo\tSpVv[3Srb36gZZN{[Xl?				MVzJcohq[mm2aX;uJI9nKFO7azDpckBidnSrIFnnUU1{fGmvdXzheIVlKGi3bXHuJHJidW:\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IFLMUmsheGixc4Doc5J6dGG2aX;uJIJ6KGOnbHz1cIFzKGG\|c3H5MEBKSzVyPUCuOFU4\|ryPLh?=	NYrlV4h3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY5ODZpPkK0O\|I3QDB4PD;hQi=>
Rec1	NGG0eHJHfW6ldHnvckBie3OjeR?=	NULYd2w4Oi53IIXN	MlHvOkBpenN?		MmnGTY5pcWKrdHnvckBw\iCEVFugdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLlZ\|Eh[2WubIOgZZQhOi53IIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q>	M3q2[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKyPFc4Lz5{NUKyNlg4PzxxYU6=
Rec1	M{XGXmZ2dmO2aX;uJIF{e2G7	MYeyMlUhfU1?	NHe4N4s3KGi{cx?=		NH;RfGtKdmirYnn0bY9vKG:oIGP5b{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVoVkOSClZXzsd{BifCB{LkWgeW0hcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>?	Mn\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkK4O\|coRjJ3MkKyPFc4RC:jPh?=
Rec1	NWPIZZFETnWwY4Tpc44h[XO\|YYm=	NIHCboczNjVidV2=	M4\FcVYhcHK\|		Mn;RTY5pcWKrdHnvckBw\iCOeX6gdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLlZ\|Eh[2WubIOgZZQhOi53IIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q>	NYLHNmNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlI5PzdpPkK1NlIzQDd5PD;hQi=>
SJ-GBM2	MlO0dWhVWyCjc4PhfS=>				MkKydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NYLGT3BbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MYDxTHRUKGG\|c3H5				NYnUTlVXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	M170PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NETN[Y1yUFSVIHHzd4F6				M4LkUJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NUe2cmZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NGfSXnhyUFSVIHHzd4F6				MmPSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NXH2[4hCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NYjPXVhLeUiWUzDhd5NigQ>?				MnLGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	NES4XJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NVvOemNPeUiWUzDhd5NigQ>?				MnPvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MlTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MlrldWhVWyCjc4PhfS=>				MnfCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	MkPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-RPS6 / T-RPS6 / p-4E-BP1 / T-4E-BP1 ; p-MEK / T-MEK / p-ERK / T-ERK ; p-c-RAF / T-c-RAF ; p-AKT / T-AKT / p-mTOR / T-mTOR	23535559
Growth inhibition assay	Cell viability (U87, U251 cells) ; Cell viability (GSC lines)	31043589

In vivo

R406 reduces cutaneous reverse passive Arthus reaction by approximately 86% at 5 mg/kg in prophylactic treated mice. R406 also shows efficacy in inhibiting paw inflammation in antibody-induced arthritis mouse models. ^[1] R406 does not adversely affect macrophage or neutrophil function in innate immune responses and has minimal functional immunotoxicity notwithstanding its lymphocytopenic effect. ^[4]

Protocol (from reference)

Animal Research:^[1]	Animal Models: Arthritis is induced in C57BL/6 mice by intraperitoneal injection of 150 μL of pooled sera from adult K/BxN mice. Dosages: 1 or 5 mg/kg Administration: Administered orally (Only for Reference)

References

[4] Zhu Y, et al. Toxicol Appl Pharmacol, 2007, 221(3), 268-277.

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (159.07 mM)
	Water	Insoluble
	Ethanol	0 mg/mL (0.0 mM)
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5%dmso+95%cornoil For best results, use promptly after mixing. Click to purchase: Corn Oil	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	628.63
Formula	C₂₂H₂₃FN₆O₅.C₆H₆O₃S
CAS No.	841290-81-1
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)O

Download R406 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01725230	Completed	Drug: Fostamatinib\|Drug: Rosuvastatin\|Drug: Simvastatin	Rheumatoid Arthritis	AstraZeneca	November 2012	Phase 1
NCT01598571	Completed	Drug: Fostamatinib	Healthy	AstraZeneca	May 2012	Phase 1
NCT01387308	Completed	Drug: Fostamatinib	Healthy	AstraZeneca	August 2011	Phase 1
NCT01355354	Completed	Drug: Digoxin\|Drug: Fostamatinib	Healthy Volunteers\|Rheumatoid Arthritis	AstraZeneca	June 2011	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
What’s the difference between S1533 and S2194?

Answer:
S1533 and S2194 are two different forms of R406. S1533 is the free base form, containing only R406 molecule without a acid added to it. S2194 has an additional C6H6O3S acid on it which makes the molecule a salt form. The free base and salt forms have same biology activities. Free base has a lower molecular weight and salt form has a better solubility in DMSO.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):